Journal of Medical Biochemistry最新文献

{"title":"Comparing outcomes of systemic anticoagulant therapy and vascular interventional therapy in cerebral venous sinus thrombosis with concurrent brain parenchymal injury: Biomarker analysis.","authors":"Jinhui Qin, Xingyang Zhu, Xiaoli Wang, Xiangjie Cheng","doi":"10.5937/jomb0-55011","DOIUrl":"10.5937/jomb0-55011","url":null,"abstract":"<p><strong>Background: </strong>Cerebral venous sinus thrombosis (CVST) with concurrent brain parenchymal injury is a severe and complex condition that requires effective treatment strategies and long-term follow-ups. This study aimed to evaluate the prognostic value of serum caspase-cleaved cytokeratin-18 (CCCK-18), neuron-specific enolase (N SE), S-100P, nerve growth factor (N GF), and CRP D-Dimer, and EPO in CVST treatment.</p><p><strong>Methods: </strong>Ninety patients with CVST combined with parenchymal brain had undergone systemic anticoagulant therapy (SAT group) or vascular interventional therapy (VIT group) at Nanyang Second General Hospital from January 2021 to January 2024 were evaluated in this study with 45 patients in each group. Three months after discharge, mRS, NIHSS, GCS, and patients' quality of life were assessed. Peripheral blood samples were collected to measure CRP D-Dimer, EPO, and CCCK-18 level changes. The levels of serum neuron-specific enolase (NSE), S100P, and nerve growth factor (NGF) were compared before and at 3 and 7 days post-treatment. Follow-up at six months post-discharge included calculations of mortality and recanalisation rates.</p><p><strong>Results: </strong>At 3 months post-discharge, 11.1% of VIT patients had an mRSS2, compared to 35.6% in the SAT group (P< 0.05). The VIT group also had lower NIHSS scores, higher GCS and SF-36 scores, and lower serum CRP EPO, and CCCK-8 levels (P< 0.05). NSE and S-100P levels were lower in the VIT group at 7 days post-treatment (P< 0.05), while NGF levels were higher at 3 days post-treatment (P< 0.05). Follow-up showed no significant difference in survival rates (88.9% vs 95.6%). Still, the VIT group had a lower proportion of patients with mRS>2 (20.0% vs 42.2%) and a higher complete recanalisation rate (73.3% vs 53.3%) (both P< 0.05).</p><p><strong>Conclusions: </strong>Combined SAT with neurovascular interventional thrombectomy benefits patients with CVST and concurrent brain parenchymal injury by promoting recovery of neurological deficits and consciousness, achieving vascular recanalisation.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1038-1049"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of SYSMEX CN-6000 and STAGO STA-R: Effects of hemolysis and lipemia.","authors":"Seren Orhan, Elif İşbilen","doi":"10.5937/jomb0-56377","DOIUrl":"10.5937/jomb0-56377","url":null,"abstract":"<p><strong>Background: </strong>Routine coagulation testing is critical in diagnosing hemostatic disorders and monitoring anticoagulant therapy. The SYSMEX CN-6000 and STAGO STA-R analyzers utilise different clot detection methods, which may impact test results. This study evaluates the analytical performance of these two automated coagulation analysers and examines the effects of hemolysis and lipemia on routine coagulation tests.</p><p><strong>Methods: </strong>Blood samples were collected from patients at Gaziantep University Şahinbey Research and Application Hospital and analysed for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FBG), and D-dimer using both analysers. Precision, method comparison, and interference studies were conducted following CLSI guidelines. Hemolysis and lipemia were induced in vitro, and their effects on test results were evaluated based on Fraser's criteria.</p><p><strong>Results: </strong>All precision study CV values were within the acceptable limits of biological variation. APTT results exhibited a significant systematic difference between analysers (r= 0.872), whereas PT (INR), FBG, and D-dimer showed strong correlations (r> 0.945). Hemolysis had a minimal impact at lower concentrations (<1 g/L). However, at 4 g/L, PT bias increased to 2.8% for the CN-6000 and 2.0% for the STA-R, with similar increases observed in APTT and FBG. Lipemia significantly affected CN-6000, which failed to produce PT results at triglyceride levels 14 mmol/L and APTT/FBG results at 28 mmol/L. In contrast, STA-R provided results with biases below 7.3% at all lipemia levels.</p><p><strong>Conclusions: </strong>Both analysers demonstrated strong analytical performance, though methodological differences influenced APTT measurements. Hemolysis had a minor impact within Fraser's acceptable bias limits, whereas CN-6000 exhibited performance limitations in severely lipemic samples, necessitating preanalytical lipid-reducing strategies. These findings underscore the need for expanded reference range studies and optimised laboratory workflows to enhance coagulation testing reliability.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"976-984"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum levels of AFP and CA19-9 after intraoperative radiotherapy combined with drug therapy on liver and pancreatic tumors.","authors":"Xin Jia, Zongliang Jiang","doi":"10.5937/jomb0-56627","DOIUrl":"10.5937/jomb0-56627","url":null,"abstract":"<p><strong>Background: </strong>To explore the efficacy of intraoperative radiotherapy combined with drug therapy on serum levels of AFP and CA19-9 for liver and pancreatic tumours to provide more effective treatment strategies for clinical practice.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 190 patients with liver and pancreatic tumours who underwent surgical resection combined with intraoperative radiotherapy in the hospital from March 2023 to September 2024. The patients were segmented into an experimental group (intraoperative radiotherapy combined with drug therapy, n = 95) and a control group (traditional treatment, n = 95) at random. After surgical resection, the experimental group accepted IORT targeted drugs, and immunomodulators. The control group received surgical resection and chemotherapy or external radiation therapy. The leading observation indicators include tumour marker levels, biochemical indicators, recurrence rate, survival rate, quality of life, postoperative complications, pain score, and psychological status.</p><p><strong>Results: </strong>The levels of AFP and CA19-9 in the experimental group decreased by 16.2 ng/mL and 74.7 U/mL, which surpassed those in the control group (P< 0.05). After treatment, the liver function indicators of the experimental group significantly improved (ALT decreased from 32 .1± 12.5 U/L to 22.4± 10.1 U/L, P = 0.00), and renal function also improved. The recurrence and metastasis rates in the experimental group were lower (P< 0.05). Although there was no discrepancy in common adverse reactions, the experimental group had a lower incidence of adverse reactions in radiation dermatitis and infection (P< 0.05). The survival curve demonstrated that the survival rate of the experimental group was higher (P< 0.05).</p><p><strong>Conclusions: </strong>Intraoperative radiotherapy combined with drug therapy has shown outstanding efficacy in treating liver and pancreatic tumours, effectively reducing tumour marker levels, improving liver and kidney function, reducing recurrence and metastasis rates, and improving survival rates and life quality while reducing postoperative complications and adverse reactions. This comprehensive treatment plan provides a new, effective strategy for treating liver and pancreatic tumours.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1127-1140"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum interleukin-6, tumour necrosis factor-a, D-dimer after recombinant human brain natriuretic peptide combined with levosimendan in patients with heart failure.","authors":"Yujing Zhang, Pingyan Fei, Xinyu Liu","doi":"10.5937/jomb0-56202","DOIUrl":"10.5937/jomb0-56202","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the impact of recombinant human brain natriuretic peptide (Rh-BNP) combined with levosimendan on therapeutic efficacy, inflammatory markers, and nutritional status in patients with heart failure (HF).</p><p><strong>Methods: </strong>A total of 162 heart failure patients treated between March 2022 and March 2024 were randomly assigned to three treatment groups: Group 1 received conventional therapy plus Rh-BNP Group 2 received conventional therapy plus levosimendan, and Group 3 received a combination of both Rh-BNP and levosimendan, along with nutritional support. Efficacy was assessed regarding cardiac function, renal function, inflammatory biomarkers (IL-6, TNF-a), nutritional status, and quality of life.</p><p><strong>Results: </strong>All three treatment groups improved cardiac and renal function, reduced inflammatory markers, and enhanced nutritional status. However, the combination therapy group (Group 3) demonstrated the most significant improvements across all parameters, including a greater reduction in IL-6 and TNF-a levels and an improvement in the Mini Nutritional Assessment (MNA) score. Additionally, the combination treatment led to marked improvements in quality of life and reduced symptoms of depression and anxiety compared to the other groups (P< 0.05).</p><p><strong>Conclusions: </strong>Rh-BNP combined with levosimendan, alongside nutritional support, offers significant benefits in treating heart failure, enhancing cardiac function, reducing inflammation, improving nutritional status, and improving the overall quality of life for patients.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1100-1109"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum level of TNF-a, IL-1 and IL-6 and serum biomarkers after nutritional change in patients' ventilator-associated pneumonia.","authors":"Lu Peng, Wang Kun, Zheng Lihua, Li Dongliang, Zhang Jie, Su Ziqin","doi":"10.5937/jomb0-56222","DOIUrl":"10.5937/jomb0-56222","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;This study aims to evaluate the effects of high-protein nutritional support (HPNS) combined with probiotics (Bifid Triple Viable Capsule) on the nutritional status, biochemical markers, and immune function in critically ill patients (CIPs) requiring mechanical ventilation, with a focus on preventing ventilator-associated pneumonia (VAP). The study explores how this intervention impacts serum albumin, prealbumin, and inflammatory cytokines (TNF-a, IL-1, IL-6), key nutritional and immune function indicators.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study included 86 critically ill patients requiring mechanical ventilation in the ICU. Participants were randomly assigned to either a research group (n=46) receiving HPNS combined with probiotics (Bifid Triple Viable Capsule) or a control group (n=40) receiving standard nutritional support. The primary outcomes included changes in serum albumin, prealbumin, and inflammatory cytokines (TNF-a, IL-1, IL-6) and the incidence of VAP The study duration was 3 weeks, and biochemical markers and clinical outcomes were assessed at baseline and post-intervention. The patients' body mass index (BMI) and body weight are calculated and compared. A spectrophotometer measures the content of serum protein. The prevalence of ventilator-associated pneumonia is analysed by sputum gram staining. The clinical symptoms of patients with ventilator-associated pneumonia during ICU are monitored. ELISA detects serum levels of inflammatory cytokines TNF-a, IL-1 and IL-6.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The research group demonstrated significant improvements in serum albumin and prealbumin levels and a lower TNF-a, IL-1, and IL-6 ratio than the control group (P&lt; 0.05). The incidence of ventilator-associated pneumonia (VAP) was significantly lower in the research group (6.52%) compared to the control group (30%, P&lt;0.05). Additionally, the research group showed higher BMI and body weight (P&lt; 0.05), suggesting improved nutritional status following the intervention.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;High-protein nutritional support combined with probiotics can significantly raise the nutritional conditions of critically ill patients and effectively prevent ventilator-associated pneumonia. This intervention enhanced key biochemical markers, such as serum albumin, prealbumin, and the albumin/total protein ratio, all of which are important indicators of nutritional status. The improvement in these markers suggests that HPNS supports tissue repair and immune function, which are crucial for recovery in ICU patients. Additionally, the combination of HPNS and probiotics reduced serum levels of inflammatory cytokines (TNF-a, IL-1, IL-6), which are commonly elevated in critically ill patients and contribute to developing infections like VAP By regulating the inflammatory response, this intervention may help reduce the risk of infection and promote faster recovery. The results of this study highlight the potential ","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1074-1082"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in acute cerebral infarction patients.","authors":"Tinghuan Wang, Fei Wang, Xinglu Dong, Xiaofeng Liu, Zhiyu Cui, Yingshuai Shi","doi":"10.5937/jomb0-55111","DOIUrl":"10.5937/jomb0-55111","url":null,"abstract":"<p><strong>Background: </strong>To explore the Diagnostic value of serum brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), plasma viscosity (PV) as well as fibrinogen (FIB) in patients receiving butylphthalide and sodium chloride injection in combination with atorvastatin calcium in acute cerebral infarction patients.</p><p><strong>Methods: </strong>Eighty ACI patients treated at our hospital between January 2022 and January 2024 were included as study participants, followed by divided into the control group (CG) and study group (SG). The CG was given atorvastatin calcium tablets. Based on the CG, the SG received a butylphthalide sodium chloride injection. The clinical efficacy, neurological impairment, daily living ability, hemorheological indicators, neurobiochemical indicators, and occurrence of adverse reactions in the two groups were compared.</p><p><strong>Results: </strong>Compared to the CG, the SG's total effective clinical effect rate was significantly higher (P<0.05). After therapy, the NIHSS score in the SG showed a significant reduction relative to the CG, and the BI score in the SG was significantly higher relative to the CG (P<0.05). The whole blood high shear viscosity, whole blood low shear viscosity, PV, HCT, and FIB levels in the SG, were significantly reduced relative to the CG (P< 0.05). The improvements of BDNF NSE, and GFAP levels in the SG were significantly superior to the CG (P< 0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).</p><p><strong>Conclusions: </strong>The combination of butylphthalide sodium chloride injection and atorvastatin calcium tablets significantly improved clinical outcomes in ACI patients by improving neurological function, daily living ability, cerebral hemodynamics, and neurobiochemical markers. This therapeutic regimen offers a promising approach to ACI management and warrants further clinical promotion. The novel aspect of this study lies in its comprehensive evaluation of both neurological and hemodynamic improvements, highlighting the potential synergistic benefits of this combined therapy.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 5","pages":"1092-1099"},"PeriodicalIF":1.5,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the effects of citicoline and vascular rehabilitation capsules on neurotrophic and inflammatory factors in patients with cerebral infarction.","authors":"Dongyun Wu, Jiajun Pan, Xinhong Fang, Zhongjun Chen","doi":"10.5937/jomb0-55775","DOIUrl":"10.5937/jomb0-55775","url":null,"abstract":"<p><strong>Background: </strong>Butylphthalide (BP) is commonly used to treat vascular dementia (VD) following cerebral infarction (CI), but BP alone has limited efficacy. BP in combination with citicoline (COPC) or vascular rehabilitation capsules (VRC) is common in clinical practice, but few studies have compared the differences between these two treatment options.</p><p><strong>Methods: </strong>Ninety-eight patients with VD after CI who were seen in our hospital from April 2020 to June 2022 were selected as the study population. Among them, 52 patients received BP combined with COPC (BP+COPC group), while the rest 46 received BP combined with VRC (BP+VRC group). Fasting venous blood was drawn from the patients before and after treatment. The levels of neurotrophic factor [nerve growth factor (NGF), neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF)], oxidative stress [superoxide dismutase (SOD), malondialdehyde (MDA)], and inflammatory factors [Tumor necrosis factor-a (TNF-a), Interleukin-1 (IL-1b), C-reactive protein (CRP)] were measured. Cognitive and neurological improvements were assessed using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) and the National Institute of Health Stroke Scale (NIHSS). In addition, the patient's cerebral hemodynamics were examined by CT.</p><p><strong>Results: </strong>After treatment, LOTCA increased in both groups and was higher in the BP+COPC group than in the BP+VRC group (P<0.05), while NIHSS decreased in the BP+COPC group than in the BP+VRC group (P<0.05). NSE, MDA, IL-1 , CRP, and TNF-a decreased in both groups after treatment, while NGF, BDNF, and SOD increased, again with more significant changes in the BP+COPC group (P<0.05). In addition, cerebral hemodynamics was more favourable in the BP+COPC group than in the BP+VRC group (P<0.05).</p><p><strong>Conclusions: </strong>BP combined with COPC has superior improvement in neurologic function in patients with VD after CI.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 4","pages":"724-730"},"PeriodicalIF":1.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum CA125, CA199, estradiol, FSH, IL-6, TNF-a in endometriosis after administration of Tripterygium wilfordii glycosides.","authors":"Fangdan Xu, Ying Xu, Jianping Qiu","doi":"10.5937/jomb0-56632","DOIUrl":"10.5937/jomb0-56632","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the therapeutic effects of Tripterygium wilfordii glycosides on endometriosis (EMs) and their effects on serum sex hormone levels, tumour markers, and inflammatory factors (serum CA125, CA199, Estradiol, FSH, IL-6, TNF-a).</p><p><strong>Methods: </strong>A total of 108 patients were randomly divided into control, progesterone, and Tripterygium wilfordii glycoside-treated groups, each receiving treatment for three months. The clinical efficacy and serum levels of estradiol, follicle-stimulating hormone, tumour markers (cancer antigen125 and cancer antigen199), and pro-inflammatory cytokines were compared before and after treatment.</p><p><strong>Results: </strong>The Tripterygium wilfordii glycoside group exhibited a significantly higher clinically effective rate (90.74% versus 75.93%) and more significant reductions in estradiol, follicle-stimulating hormone, cancer antigen125, cancer antigen199, IL-6, TNF-a, and HSCRP levels than the control group.</p><p><strong>Conclusions: </strong>Tripterygium glycosides exhibit significant clinical efficacy in treating patients with EMS by significantly improving serum sex hormone levels, reducing tumour marker levels, alleviating inflammatory reactions, and exerting minimal toxic side effects.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 4","pages":"770-775"},"PeriodicalIF":1.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling genetic predisposition and oxidative stress in vitiligo development and the role of artificial intelligence (AI) in diagnosis and management.","authors":"Hristina Kocić, Torello Lotti, Tatjana Jevtović-Stoimenov, Uwe Wollina, Yan Valle, Stevo Lukić, Aleksandra Klisić","doi":"10.5937/jomb0-56661","DOIUrl":"10.5937/jomb0-56661","url":null,"abstract":"<p><p>Vitiligo is an autoimmune disorder with a complex genetic and epigenetic aetiology, characterised by progressive skin depigmentation. Recent advancements in artificial intelligence (AI) have greatly impacted the understanding, diagnosis, and treatment of vitiligo. The genetic basis of vitiligo is linked to multiple single nucleotide polymorphisms (SNPs) in genes associated with immune function, apoptosis, and melanogenesis, necessitating the integration of AI for more efficient diagnostic tools and personalised therapies. Genome-wide association studies (GWAS) have identified approximately 50 vitiligo-susceptibility genes, including PTPN1, PTPN22, NLRP1, FASLG, and TYR. These genes influence the immune response and melanocyte function, with the transcription factor Nuclear Factor kappa B (NF-kB), playing a central role in inflammatory responses and redox signaling induced by oxidative stress, in conjunction with antioxidant enzymes such as GPx, GST, SOD, and CAT. AI technologies offer a promising avenue for diagnosing vitiligo by combining genetic, clinical, and imaging data, allowing for more accurate classification and personalised treatment strategies. By analysing vast datasets, AI algorithms can identify patterns within complex genetic markers and clinical features, facilitating earlier and more precise detection of vitiligo. Furthermore, AI-driven approaches can optimise therapeutic monitoring, enabling real-time treatment efficacy and disease progression assessment. Integrating AI in vitiligo genetic diagnostics can revolutionise the monitoring of the disorder, improving patient outcomes through personalised, data-driven interventions.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 4","pages":"713-723"},"PeriodicalIF":1.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of bone metabolism and inflammatory markers in tibiofibular fractures following closed reduction and fixation: A retrospective study.","authors":"Lingfeng Li","doi":"10.5937/jomb0-55571","DOIUrl":"10.5937/jomb0-55571","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the effectiveness and safety of closed reduction and internal fixation (CRIF) versus closed reduction and external fixation (CREF) in treating tibiofibular fractures, focusing on their impact on bone metabolism and inflammatory responses.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of 95 patients with tibiofibular fractures, categorised into the CRIF group (CRIFG) and the CREF group (CREFG). Clinical efficacy, Visual Analogue Scale (VAS) scores, serum bone metabolism markers, serum inflammatory cytokines, Generic Quality of Life Inventory-74 (GQOLI-74) scores, and adverse reactions (AR) were compared between the groups.</p><p><strong>Results: </strong>The total clinical efficacy rates were 80.49% (33/41) in the CRIFG and 85.19% (46/54) in the CREFG (P>0.05). Compared to CRIFG, the CREFG group exhibited significantly lower VAS scores and higher GQOLI-74 scores across all dimensions. Additionally, the CREFG group showed increased levels of serum osteocalcin (BGP), bone alkaline phosphatase (BALP), and N-terminal propeptide of type 1 procollagen (P1NP), along with decreased levels of type I collagen carboxy-terminal peptide b special sequence (b-CTX). Inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-1b, and tumour necrosis factor-a (TNF-a), were significantly lower in the CREFG group. The total AR rate was also lower in CREFG (18.52% vs. 31.71%, P<0.05).</p><p><strong>Conclusions: </strong>Compared to CRIF, CREF treatment is more effective in reducing pain, enhancing bone metabolism, alleviating inflammatory responses, and improving the overall quality of life (QoL) in patients with tibiofibular fractures.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 4","pages":"863-871"},"PeriodicalIF":1.5,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12363362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}